Figures & data
Table I. Species of Mycobacteria that cause tuberculosis.
Table II. Rate of tuberculosis cases by race/ethnicity in United States.
Table III. Classification of antitubercular drugs.
Table IV. Side effects of Anti TB drugs.
Table V. Salient features of drug carriers.
Table VI. Outcomes of liposome-based drug delivery systems in the treatment of TB.
Table VII. Outcomes of nanoparticle-based drug delivery systems in the treatment of TB.
Table VIII. Outcomes of microparticle/microsphere-based drug delivery systems in the treatment of TB.
Table IX. Outcomes of solid lipid nanoparticle based drug delivery systems in the treatment of TB.
Vyas SP, Kannan ME, Jain S, Mishra V, Singh P. 2004. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm. 269:37–49. Gangadharam PR, Ashtekar DA, Ghori N, Goldstein JA, Debs RJ, Duzgunes N. 1991. Chemotherapeutic potential of free and liposome encapsulated streptomycin against experimental Mycobacterium avium complex infections in beige mice. J Antimicrob Chemother. 28:425–435. Garg T, Goyal AK, Arora S, Murthy R. 2012a. Development, optimization & evaluation of porous chitosan scaffold formulation of gliclazide for the treatment of type-2 diabetes mellitus. Drug Deliv Lett. 2:251–261. Klemens SP, Cynamon MH, Swenson CE, Ginsberg RS. 1990. Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother. 34:967–970. El-Ridy MS, Mostafa DM, Shehab A, Nasr EA, Abd El-Alim S. 2007. Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis. Int J Pharm. 330:82–88. Gabor F, Bogner E, Weissenboeck A, Wirth M. 2004. The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv Drug Deliv Rev. 56:459–480. Goyal G, Garg T, Malik B, Chauhan G, Rath G, Goyal AK. 2013b. Development and characterization of niosomal gel for topical delivery of benzoyl peroxide. Drug Deliv. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. 2003. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother. 52:981–986. Sharma A, Sharma S, Khuller GK. 2004. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother. 54:761–766. Gelperina S, Kisich K, Iseman MD, Heifets L. 2005. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med. 172:1487–1490. Parnami N, Garg T, Rath G, Goyal AK. 2013. Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. Artif Cells Nanomed Biotechnol. Qurrat ul A, Sharma S, Khuller GK, Garg SK. 2003. Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. J Antimicrob Chemother. 51:931–938. Barrow EL, Winchester GA, Staas JK, Quenelle DC, Barrow WW. 1998. Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob Agents Chemother. 42:2682–2689. Lu D, Garcia-Contreras L, Xu D, Kurtz SL, Liu J, Braunstein M, et al. 2007. Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B. Pharm Res. 24:1834–1843. Pandey R, Khuller GK. 2005a. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother. 55:430–435. Suarez S, O’Hara P, Kazantseva M, Newcomer CE, Hopfer R, Mcmurray DN, Hickey AJ. 2001. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res. 18:1315–1319. Pandey R, Khuller GK. 2005b. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb). 85:227–234. Pandey R, Sharma S, Khuller GK. 2005. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinb). 85: 415–420. Ahmad Z, Sharma S, Khuller GK. 2005. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents. 26:298–303. Garcia-Contreras L, Fiegel J, Telko MJ, Elbert K, Hawi A, Thomas M, et al. 2007. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 51:2830–2836. Kaur M, Garg T, Rath G, Goyal AK. 2014a. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit Rev Ther Drug Carrier Syst. 31:49–88.